These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 25196073

  • 1. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
    Koopmans SM, Schouten HC, van Marion AM.
    Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
    [Abstract] [Full Text] [Related]

  • 2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 3. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
    Koopmans SM, van Marion AM, Schouten HC.
    Neth J Med; 2012 May 06; 70(4):159-67. PubMed ID: 22641623
    [Abstract] [Full Text] [Related]

  • 4. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
    Lyu XD, Li YW, Guo Z, Xin YP, Hu JY, Fan RH, Song YP.
    Zhonghua Nei Ke Za Zhi; 2020 Jan 01; 59(1):35-39. PubMed ID: 31887834
    [Abstract] [Full Text] [Related]

  • 5. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.
    Asian Pac J Cancer Prev; 2016 Jan 01; 17(3):923-6. PubMed ID: 27039813
    [Abstract] [Full Text] [Related]

  • 6. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA, Khasawneh R, Kamal N, Matalka I, Al-Bishtawi M, Al-Sweedan S, Ayesh MH.
    Hematol Oncol Stem Cell Ther; 2015 Dec 01; 8(4):160-6. PubMed ID: 26256826
    [Abstract] [Full Text] [Related]

  • 7. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L, Xiao ZJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb 01; 19(1):239-43. PubMed ID: 21362261
    [Abstract] [Full Text] [Related]

  • 8. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.
    Asian Pac J Cancer Prev; 2015 Feb 01; 16(12):5013-8. PubMed ID: 26163633
    [Abstract] [Full Text] [Related]

  • 9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Feb 01; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 10. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
    Yan J, Ding YW, Wang PY, Wu YP, Zhang HC, Liu LH.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct 01; 29(5):1540-1547. PubMed ID: 34627437
    [Abstract] [Full Text] [Related]

  • 11. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
    Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM, Van Etten RA.
    Blood; 2012 Apr 12; 119(15):3550-60. PubMed ID: 22234689
    [Abstract] [Full Text] [Related]

  • 12. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
    Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G.
    Korean J Lab Med; 2010 Dec 12; 30(6):567-74. PubMed ID: 21157140
    [Abstract] [Full Text] [Related]

  • 13. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.
    FASEB J; 2012 Feb 12; 26(2):894-906. PubMed ID: 22051730
    [Abstract] [Full Text] [Related]

  • 14. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A.
    Mod Pathol; 2018 May 12; 31(5):690-704. PubMed ID: 29327708
    [Abstract] [Full Text] [Related]

  • 15. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofer S, Tichelli A, Tzankov A.
    Br J Haematol; 2009 Jul 12; 146(2):150-7. PubMed ID: 19466975
    [Abstract] [Full Text] [Related]

  • 16. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, Czuchlewski DR, Elenitoba-Johnson KS, Lim MS.
    Diagn Mol Pathol; 2012 Sep 12; 21(3):176-83. PubMed ID: 22847163
    [Abstract] [Full Text] [Related]

  • 17. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
    Fontanelli G, Baratè C, Ciabatti E, Guerrini F, Grassi S, Del Re M, Morganti R, Petrini I, Arici R, Barsotti S, Metelli MR, Danesi R, Galimberti S.
    Int J Lab Hematol; 2015 Dec 12; 37(6):766-73. PubMed ID: 26189968
    [Abstract] [Full Text] [Related]

  • 18. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Moura LG, Tognon R, Nunes NS, Rodrigues LC, Ferreira AF, Kashima S, Covas DT, Santana M, Souto EX, Perobelli L, Simões BP, Dias-Baruffi M, Castro FA.
    J Clin Pathol; 2016 Oct 12; 69(10):926-9. PubMed ID: 27402956
    [Abstract] [Full Text] [Related]

  • 19. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
    Berzoti-Coelho MG, Ferreira AF, de Souza Nunes N, Pinto MT, Júnior MC, Simões BP, Martínez-A C, Souto EX, Panepucci RA, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2016 Jul 12; 59():25-30. PubMed ID: 27282563
    [Abstract] [Full Text] [Related]

  • 20. Molecular characterization of chronic myeloproliferative neoplasias in México.
    Ruiz-Argüelles GJ, Garcés-Eisele J, Ortiz-López R, Rivas-Llamas R, Gómez-Almaguer D, Ruiz-Delgado GJ.
    Hematology; 2009 Oct 12; 14(5):261-5. PubMed ID: 19843380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.